Antihypertensive drugs and the heart

Minerva Medica

Volumn 96, Issue 4, 2005, Pages 247-260

  Diamond, J A ^a,b   Phillips, R A ^c,d  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive agents; Cardiovascular diseases; Heart

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; METOPROLOL; MINOXIDIL; NIFEDIPINE; PLACEBO; PRAZOSIN; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIASTOLE; DRUG MECHANISM; HEART; HEART FAILURE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; VENTRICULAR DYSFUNCTION, LEFT;

EID: 27844464400     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Levy D, Anderson KM, Savage D, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham heart study. Ann Int Med 1988;108:7-13.
2. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-8.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
4. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993;22:1111-6.
5. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-6.
6. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004;17(12 Pt 2):23S-30S.
7. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990;65:441-5.
8. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992;117:831-6.
9. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
10. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
11. Bromberg JE, Rinkel GJ, Algra A, Limburg M, van Gijn J. Outcome in familial subarachnoid hemorrhage. Stroke 1995;26:961-3.
12. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002;15:1021-8.
13. Schussheim AE, Diamond JA, Phillips RA. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. Am J Cardiol 2001;87:61-5.
14. Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974;35:775-81.
15. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
16. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ et al. Treatment of mild hypertension study: final results. JAMA 1993;270:713-24.
17. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
18. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-14.
19. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
20. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004;110:E1-E7.
21. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62.
22. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.
23. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.
24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
25. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569-75.
26. Stella P, Bigatti G, Tizzoni L, Barlassina C, Lanzani C, Bianchi G et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 2004;43:265-70.
27. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
28. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-8.
29. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002;25:837-42.
30. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43.
31. Gradman AH, Schmieder RE, Lins RL, Nussherger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8.
32. 2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res 2002;25:117-24.
33. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-8.
34. Molkentin JD, Lu JR, Antos CL, Markham R, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.
35. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:1090-3.
36. Nagata K, Somura F, Ohata K, Odashima M, Izawa H, Ichihara S et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002;40:168-74.
37. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-24.
38. Varo N, Iraburu MJ, Varela M, Lopez B, Etayo JC, Diez J. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000;35:1197-202.
39. Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 2000;46:298-306.
40. Suzuki J, Iwai M, Nakagami H, Wu L, Chen R, Sugaya T et al. Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 2002;106:847-53.
41. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 2003;26:89-95.
42. Collins AR, Schnee J, Wang W, Kim S, Fishbein MC, Bruemmer D et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004;43:1698-705.
43. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M et al. Role of Osteopontin in Cardiac Fibrosis and Remodeling in Angiotensin II-Induced Cardiac Hypertrophy. Hypertension 2004;43:1195-201.
44. Takahashi N, Saito Y, Kuwahara K, Harada M, Kishimoto I, Ogawa Y et al. Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 2003;26:847-53.
45. Tokudome T, Horio T, Kishimoto I, Soeki T, Mori K, Kawano Y et al. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation 2005;111:3095-104.
46. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002;25:669-76.
47. Vanderheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K, Van Schuerbeeck E et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44:2349-54.
48. Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Risteli J et al. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 2004;97:251-6.
49. Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 2003;16:1025-9.
50. Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure. Mol Cell Biochem 2003;254:265-73.
51. Graham D, Hamilton C, Beattie E, Spiers A, Dominiczak AF. Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. J Hypertens 2004;22:329-37.
52. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002;106:2118-24.
53. Chen MS, Xu FP, Wang YZ, Zhang GP, Yi Q, Zhang HQ et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004;37:889-96.
54. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003;107:1664-70.
55. Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268:1597-604.
56. Tsujimoto I, Hikoso S, Yamaguchi O, Kashiwase K, Nakai A, Takeda T et al. The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy. Hypertension 2005;45:921-6.
57. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z. In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 2002;39(2 Pt 2):332-6.
58. Glueck SB, Dzau VJ. Physiological genomics: implications in hypertension research. Hypertension 2002;39(2 Pt 2):310-5.
59. Kimura B, Mohuczy D, Tang X, Phillips MI. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension 2001;37(2 Part 2):376-80.
60. Takahashi H, Takeishi Y, Seidler T, Arimoto T, Akiyama H, Hozumi Y et al. Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy. Circulation 2005;111:1510-6.
61. Stella P, Bigatti G, Tizzoni L, Barlassina C, Lanzani C, Bianchi G et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 2004;43:265-70.
62. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al Saadi N et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005;111:3087-94.
63. Gonzalez-Fernandez RB, Altieri PI, Diaz LM, Rodriguez PJ, Fernandez J, Miranda JG et al. Effects of enalapril on heart failure in hypertensive patietns with diastolic dysfunction. Am J Hypertens 1992;5:480-3.
64. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-4.
65. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
66. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
67. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of Verapamil for Congestive Heart Failure Associated with Abnormal Left Ventricular Diastolic Filling and Normal Left Ventricular Systolic Performance. Am J Cardiol 1990;66:981-6.
68. Given BD, Lee TH, Stone PH, Dzau VJ. Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. Arch Intern Med 1985;145:281-5.
69. Hung MJ Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002;56:57-62.
70. Andersson B, Caidahl K, di Lenarda A, Warren SE, Goss F, Waldenstrom A et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996;94:673-82.
71. Nodari S, Metra M, Dei CL. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. Eur J Heart Fail 2003;5:621-7.
72. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992;117:502-10.
73. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994;271:1276-80.
74. Packer M. Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 1990;81(2 Suppl):III78-86.
75. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
76. Lorell BH, Isoyama S, Grice WN, Weinberg EO, Apstein CS. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood- perfused rabbit hearts. Circ Res 1988;63:457-67.
77. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
78. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM et al. The Pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001;344:17-22.
79. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 1993;22:318-325.
80. Erratum in: J Am Coll Cardiol 1993;22:1272.
81. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-71.
82. Hsueh WA, Law RE, Do YS. Integrins, adhesion, and cardiac remodeling. Hypertension 1998;31(1 Pt 2):176-80.
83. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004;43:739-45.
84. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003;107:2555-8.
85. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004;43:1481-8.
86. Herrmann KL, McCulloch AD, Omens JH. Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 2003;284:H1277-84.
87. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, deGroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005;11:191-5.
88. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Resetting the Hypertension Sails. Hypertension 2003;41:1178-9.